Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Matthew A. Gubens, M.D., M.S.

Matthew A. Gubens, M.D., M.S.

Assistant Clinical Professor of Medicine
Division of Hematology/Oncology
Department of Medicine

Contact Information

(415) 885-3882  Appointments
(415) 353-7151  Clinic Fax
Matthew.Gubens@ucsf.edu
Open Popup
  • 1993-1997, Yale University, New Haven, CT, BA, Ethics, Politics and Economics
  • 1998-2000, Harvard School of Public Health and Management, MS, Health Policy and Management
  • 2000-2005, Stanford University School of Medicine, MD
  • 2005-2008, UCSF, San Francisco, CA, Resident, Internal Medicine
  • 2008-2011, Stanford University, Stanford, CA, Fellow, Medical Oncology
  • American Board of Internal Medicine, Internal Medicine
  • Department of Medicine, Division of Hematology Oncology
  • Thoracic Oncology Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Thymoma & Thymic Carcinoma

Matthew Gubens, M.D., M.S. is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

His research involves designing clinical trials to study new compounds and treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine, and are actively working to translate laboratory-based findings to the clinic, especially for patients with epidermal growth factor receptor (EGFR) mutations, who are often young non-smokers.

Dr. Gubens earned his medical degree at Stanford, completed an internal medicine residency at UCSF and then a medical oncology fellowship at Stanford. He also holds an MS degree in Health Policy and Management from Harvard School of Public Health. Gubens is a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the International Thymic Malignancy Interest Group and the American College of Physicians.

 
Most recent publications from a total of 17
  1. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 Sep 28; 380(1):144-52. View in PubMed
  2. Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016 Jul; 27(7):1291-8. View in PubMed
  3. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov 1; 151(11):1206-12. View in PubMed
  4. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166. View in PubMed
  5. Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG. Oncogenic activation of the PI3-kinase p110ß isoform via the tumor-derived PIK3Cß(D1067V) kinase domain mutation. Oncogene. 2016 Mar 3; 35(9):1198-205. View in PubMed
  6. Gubens MA, Burns M, Perkins SM, Pedro-Salcedo MS, Althouse SK, Loehrer PJ, Wakelee HA. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer. 2015 Jul; 89(1):57-60. View in PubMed
  7. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21; 372(21):2018-28. View in PubMed
  8. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. NF-?B-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 7; 11(1):98-110. View in PubMed
  9. Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15; 20(24):6295-303. View in PubMed
  10. Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov; 15(6):426-32. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Matthew A. Gubens, M.D., M.S.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X